Study summary · research use only
Cerebrolysin Ameliorates Age-Induced Dendritic Spine Degeneration and Memory Decline in C57BL6 Mice
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This study in C57BL6 mice evaluated dendritic spine dynamics and recognition memory at 3, 6, 12, and 18 months of age, and tested whether chronic treatment with cerebrolysin (CBL) altered age-related changes. Aging was associated with impaired locomotor activity at 12 and 18 months and deficits in short- and long-term recognition memory versus young controls. CBL treatment was associated with increased locomotion in the 18-month group and improved short-term memory in the 12-month group. Aging reduced spine density and the proportion of thin and mushroom spines in the prefrontal cortex and dorsal hippocampus, while CBL treatment increased spine density in the dorsal hippocampus and basolateral amygdala and increased mature mushroom spine formation, along with elevated β-actin, synaptophysin, and brain-derived nerve factor expression in the 18-month group.
Abstract
Aging is associated with progressive synaptic deterioration and cognitive decline; however, therapeutic strategies capable of restoring both structural and functional deficits remain limited. This study evaluated the effects of aging on dendritic spine dynamics and recognition memory across multiple brain regions, and evaluated whether chronic treatment with cerebrolysin (CBL) could ameliorate age-related alterations (3, 6, 12 and 18 months of age). We additionally assessed the effects of CBL on key molecular markers of synaptic plasticity in aged (18-month) C57BL6 mice. Aging impaired locomotor activity (12- and 18-month groups) and produced deficits in short- and long-term recognition memory relative to young controls. Notably, CBL selectively enhanced locomotion in 18-month group and improved short-term memory in the 12-month group. At the structural level, aging reduced spine density and decreased the proportion of thin and mushroom spines in the prefrontal cortex and dorsal hippocampus, whereas CBL treatment increased spine density in the dorsal hippocampus and basolateral amygdala, and promoted the formation of mature mushroom spines in a region and age-dependent manner. Importantly, CBL elevated β-actin, synaptophysin and brain-derived nerve factor expression across multiple regions in the 18-month group. This study provides the first integrated demonstration that CBL enhances dendritic spine maturation and dendritic structural remodeling while concurrently improving cognitive outcomes within the same cohort of aged animals. Collectively, our findings position CBL as a promising therapeutic candidate to counteract age-related synaptic loss and cognitive decline, advancing current understanding of neuroprotective interventions in aging.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.